
|Articles|October 24, 2012
VIDEO: Robert Frantz, MD, FACC, Discusses Costs Associated With Pulmonary Arterial Hypertension
Robert Frantz, MD, FACC, Director, Pulmonary Hypertension Clinic, Mayo Clinic, says that the issue of cost is an important factor in treating patients with pulmonary arterial hypertension.
Advertisement
Robert Frantz, MD, FACC, Director, Pulmonary Hypertension Clinic, Mayo Clinic, says that the issue of cost is an important factor in treating patients with pulmonary arterial hypertension. Dr Frantz also says that patients with pulmonary arterial hypertension who contract a blood stream infection will most likely require costly hospitalization and run the risk of other health issues.
This video was taken on Sunday, October 21 at the CHEST 2012 conference in Atlanta, GA.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss
2
Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year
3
Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD
4
Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD
5




